

-- 23. Use of the modification A' of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to Claim 7 as a pharmaceutical preparation. --

-- 24. Use of the modification A' of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to Claim 7 for the preparation of pharmaceutical preparations for the treatment of epilepsy and subindications thereof. --

-- 25. A pharmaceutical preparation comprising a modification according to Claim 14 and pharmaceutically usable excipients and additives. --

REMARKS


Claims 3, 5-8 and 15 have been amended to remove their multiple dependencies.

Claims 9-12 have been amended to delete their alternative embodiments and to remove their multiple dependencies.

New Claims 16-25 have been added. In this connection, Claims 16-20 are directed to the embodiments excised from Claim 7, whereas Claims 21-25 are directed to the embodiments excised from Claims 9-12 and 15.

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6921



Joseph J. Borovian
Agent for Applicants
Reg. No. 26,631

Date: August 14, 1998